Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 29.
doi: 10.1111/jdv.20774. Online ahead of print.

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study

Riccardo Balestri  1 , Giulia Odorici  2 , Michela Magnano  3 , Paolo Gisondi  4 , Francesco Bellinato  4 , Simone Ribero  5 , Paolo Dapavo  5 , Luca Mastorino  5 , Martina Burlando  6 , Emanuele Cozzani  6 , Nicoletta Bernardini  7 , Concetta Potenza  7 , Anna Balato  8 , Stefano Caccavale  8 , Vito Di Lernia  9 , Francesca Peccerillo  9 , Matteo Megna  10 , Anna Campanati  11 , Francesco Loconsole  12 , Edoardo Mortato  12 , Emanuele Trovato  13 , Lucia Mantovani  2 , Giacomo Caldarola  14   15 , Clara De Simone  14   15 , Gennaro Marco Falco  14   15 , Alessandra Narcisi  16 , Angela Alfano  16 , Marco Galluzzo  17 , Angela Fico  17 , Elena Pezzolo  18 , Francesca Prignano  19 , Antonella Di Cesare  19 , Camilla Loi  20 , Francesca Satolli  21 , Maria Letizia Musumeci  22 , Romina Ortega  22 , Enzo Errichetti  23 , Valentina Dini  24 , Alessandra Michelucci  24 , Paolo Amerio  25 , Andrea Carugno  26 , Michela Tabanelli  27 , Andrea Conti  28 , Claudio Guarneri  29 , Federico Bardazzi  20 , Giulia Rech  1
Affiliations

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study

Riccardo Balestri et al. J Eur Acad Dermatol Venereol. .
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Bernardini N, Dattola A, Rossi R, Pagnanelli G, Amerio P, Atzori L, et al. Efficacy and safety of intra‐class switching from Ixekizumab to Secukinumab in patients with plaque psoriasis: a multicenter retrospective study. J Pers Med. 2024;14(12):1169.
    1. Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547–1548.
    1. Kimmel G, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti‐interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857–859.
    1. Yeung J, Vender R, Turchin I, Shukla R, Maari C, Hong CH, et al. Brodalumab success in patients with moderate‐to‐severe psoriasis who failed previous interleukin‐17A inhibitors. J Am Acad Dermatol. 2021;84(4):1169–1171.
    1. Kromer C, Wilsmann‐Theis D, Gerdes S, Krebs S, Pinter A, Philipp S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL‐17A blocker ‐ a retrospective multicenter study. J Dermatolog Treat. 2021;32(8):878–882.

LinkOut - more resources